Acumen Pharmaceuticals' lead Alzheimer's drug sabirnetug failed to show clinical efficacy in the ALTITUDE-AD trial. See why ABOS stock is downgraded to a sell.
CRYSTAL LAKE, Ill., September 14, 2026--Aptar and Massachusetts General Hospital Collaborate on Platform to Establish Predictive, Data-Driven Model for Advancing Nose-to-Brain Drug Delivery
This is the newest page. Registered accounts read further back.